CAI
CAI
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
6
$2.39M
Insider Sales
4
$28.86M
Total Volume
$31.25M
18 transactions
Net Activity
$26.47M
Net selling
Sentiment Rating
Neutral / BalancedCEO Conviction Index
No Recent Signal
Key Drivers
- •Heavy distribution: sales represent 92% of total transaction value.
- •Cluster buying: 5 unique insiders purchased shares, showing strong alignment.
- •High accumulation: total purchase value exceeds $1M.
- •Significant liquidation: total sale value exceeds $10M.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Multiple Insiders
S - Sale Insiders
$102.42B total
Spetzler David Baxley
Pres
$14.84M total
Brille Brian J
See Remarks
$12.76M total
Power Luke Thomas
See Remarks
$1.65M total
Halbert Jon
Dir
$990K total
Quick Actions
CAI has an insider buy conviction of 8%, compared to the Unknown sector buy average of 6%.
Over the last 90 days, corporate insiders at CAI (CAI) engaged in a total of 18 transactions reported via SEC Form 4 filings. Among these, 6 were open-market purchases and 4 were sales. The total volume of insider trading reached $31.25M.
The net insider activity for CAI shows a net selling bias of $26.47M. This activity represents a 8% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Multiple Insiders (P - Purchase Insiders), who traded 1.46M shares valued at $99.36B on May 15, 2026.
Caris Life Sciences, Inc. (CAI) stock price, news, quote and history
Caris Life Sciences (NDQ:CAI): Its Molecular Profiling Business Is Already Working, Now Investors Must Decide If Its Precision Oncology Platform Can
Caris Life Sciences (NasdaqGS:CAI) Stock Forecast & Analyst Predictions
Caris Life Sciences, Inc. (NASDAQ:CAI) Stock Has Average Price Target of $31.18
$CAI stock is down 10% today. Here's what we see in our data. | CAI Stock News
CAI - Caris Life Sciences Inc Stock Price and Quote
FAQs About CAI Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for CAI.